Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future

Citation
Rh. Muller et al., Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future, ADV DRUG DE, 47(1), 2001, pp. 3-19
Citations number
52
Categorie Soggetti
Pharmacology & Toxicology
Journal title
ADVANCED DRUG DELIVERY REVIEWS
ISSN journal
0169409X → ACNP
Volume
47
Issue
1
Year of publication
2001
Pages
3 - 19
Database
ISI
SICI code
0169-409X(20010323)47:1<3:NAPDFI>2.0.ZU;2-J
Abstract
An increasing number of newly developed drugs are poorly soluble: in many c ases drugs are poorly soluble in both aqueous and organic media excluding t he traditional approaches of overcoming such solubility factors and resulti ng in bioavailability problems. An alternative and promising approach is th e production of drug nanoparticles (i.e. nanosuspensions) to overcome these problems. The major advantages of this technology are its general applicab ility to most drugs and its simplicity. In this article, the production of nanoparticles on a laboratory scale is presented, special features such as increased saturation solubility and dissolution velocity are discussed, and special applications are highlighted, for example, mucoadhesive nanosuspen sions for oral delivery and surface-modified drug nanoparticles for sire-sp ecific delivery to the brain. The possibilities of large scale production - the prerequisite for the introduction of a delivery system to the market a re also discussed. (C) 2001 Elsevier Science B.V. All rights reserved.